Tarsus Pharmaceuticals
IPOHome | Tarsus
Public · United States · $60.0M raised
- Business Model
- B2B
- Website
- tarsusrx.com
- Total Funding
- $60.0M
- Last Round
- $60.0M Series BJan 2020
- Rounds
- 1
- Type
- Public
About
Biopharmaceutical company developing eye care therapies, including XDEMVY, the first FDA-approved Demodex blepharitis treatment.
Summary
Tarsus Pharmaceuticals is a Biotech company based in United States. It has raised $60.0M in total across 1 round, most recently a $60.0M Series B round in Jan 2020. Investors include Vivo Capital, Frazier Healthcare and Flying L Partners.
Tech & App Stack
6 technologies & apps tracked
Create a free account to track companies, build lists, and unlock premium data like the full tech & app stack.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Funding History
Oct 2020
Sign up to see all 2 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biopharmaceutical services company
Specialty pharmaceutical company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...